Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been assigned an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $91.20.

Several research analysts have commented on HALO shares. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Leerink Partners raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $83.00 to $110.00 in a report on Friday, August 7th. UBS Group reiterated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, June 3rd. HC Wainwright restated a “buy” rating and set a $115.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, September 2nd. Finally, Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th.

Halozyme Therapeutics Price Performance

HALO stock opened at $107.20 on Friday. The company’s 50-day moving average price is $93.73 and its two-hundred day moving average price is $76.97. The firm has a market cap of $12.17 billion, a P/E ratio of 32.00, a P/E/G ratio of 0.41 and a beta of 0.88. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics has a 12 month low of $61.22 and a 12 month high of $111.15.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, analysts anticipate that Halozyme Therapeutics will post 8.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Mahesh Krishnan sold 7,304 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the sale, the chief executive officer directly owned 767,780 shares in the company, valued at $82,482,605.40. This trade represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 72,478 shares of company stock valued at $7,370,004. 2.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of HALO. California State Teachers Retirement System increased its holdings in Halozyme Therapeutics by 7,724.2% in the 2nd quarter. California State Teachers Retirement System now owns 10,668,044 shares of the biopharmaceutical company’s stock worth $834,988,000 after purchasing an additional 10,531,698 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Halozyme Therapeutics during the second quarter valued at about $214,504,000. William Blair Investment Management LLC bought a new stake in shares of Halozyme Therapeutics during the second quarter worth about $196,540,000. Norges Bank bought a new stake in shares of Halozyme Therapeutics during the fourth quarter worth about $128,201,000. Finally, Jupiter Topco LLC acquired a new position in shares of Halozyme Therapeutics in the second quarter valued at approximately $105,570,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of medicines. The company’s primary technology is ENHANZE, which uses recombinant human hyaluronidase PH20 to facilitate the subcutaneous delivery of certain biologic and other injectable therapies that might otherwise require intravenous infusion.

Halozyme provides ENHANZE technology to pharmaceutical and biotechnology partners through licensing and collaboration agreements.